Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

NCT02685852 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the drug exenatide can help manage blood sugar levels in people who experience low blood sugar due to high insulin levels after eating.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 11 people

Who can join Ages 18–60 · all sexes

Timeline Started 2016-02 · est. completion 2019-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02685852 ↗

Description as written by the study sponsor.

The purpose of the study is to evaluate the effectiveness of exenatide in adults experiencing episodes of hyperinsulinemic hypoglycemia following Roux-en-Y bariatric surgery.

Treatments tested

Exenatide also known as Byetta Drug

Exenatide at a dose of 5 mcg
Acarbose Drug

Acarbose at a dose of 25 mg
Exenatide Placebo Drug

Placebo for Exenatide
Acarbose Placebo Drug

Placebo for Acarbose

Main thing measured	Glucose area under the curve (AUC) following treatment for each 4-hour test period
Sponsor	University of Minnesota
Conditions studied	Hyperinsulinemic Hypoglycemia
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02685852 ↗